KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy
Laura Favazza, Christine M. Parseghian, Cihan Kaya, Marina N. Nikiforova, Somak Roy, Abigail I. Wald, Michael S. Landau, Siobhan Proksell, Jeffrey Dueker, Elyse Johnston, Randall E. Brand, Nathan Bahary, Vikram Gorantla, John C. Rhee, James F. Pingpank, Haroon A. Choudry, Kenneth Lee, Alessandro Paniccia, Melanie Ongchin, Amer H. Zureikat, David L. Bartlett, Aatur D. Singhi
Topics & Concepts
KRASNeuroblastoma RAS viral oncogene homologHRASMedicineColorectal cancerInternal medicineOncologyConcomitantTargeted therapyEGFR inhibitorsCancerEpidermal growth factor receptorColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerLung Cancer Treatments and Mutations